Amoxicillin/Potassium Clav
Brand names: Amoxicillin-Clavulanate Pot Er, Amoxicillin-Clavulanate Potass
Part of: Common antibiotics
At a glance
- Medicare prescriptions, 2024
- 5,742,091
- Medicare drug cost
- $53.7M
- Average cost per prescription
- $9.35
- Clinicians who prescribed it
- 209,028
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Amoxicillin and clavulanate potassium for oral suspension is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta-lactamase inhibitor, indicated for the treatment of infections caused by designated susceptible (confirmed or suspected) beta-lactamase-producing microorganisms: Lower Respiratory Tract Infections Amoxicillin and Clavulanate Potassium for Oral Suspension: pediatric patients weighing less than 40 kg, and in adult and pediatric patients who cannot swallow tablets Acute Bacterial Sinusitis Amoxicillin and Clavulanate Potassium for Oral Suspension: pediatric patients weighing less than 40 kg, and in adult and pediatric patients who cannot swallow tablets Acute Bacterial Otitis Media Amoxicillin and Clavulanate Potassium for Oral Suspension: pediatric patients weighing less than 40 kg, and in adult and pediatric patients who cannot swallow tablets Skin and Skin Structure Infections Amoxicillin and Clavulanate Potassium for Oral Suspension: pediatric patients weighing less than 40 kg, and in adult and pediatric patients who cannot swallow tablets Urinary Tract Infections Amoxicillin and Clavulanate Potassium for Oral Suspension: pediatric patients weighing less than 40 kg, and in adult and pediatric patients who cannot swallow tablets Limitations of Use Therapy may be initiated before bacteriological results are available when…
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nurse Practitioners 27.3%
- Family Medicine 19.6%
- Internal Medicine 15.7%
- Physician Assistants 13.8%
- Emergency Medicine 4.4%
- Dentists (general) 2.6%
- ENT (Otolaryngology) 2.0%
- Podiatrists 1.8%
- Urology 1.7%
- Hospitalist 1.7%
- General Practice 1.3%
- Pulmonology 1.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 43% from 2019 to 2024.
Biggest change by state since 2019
- Maine +68%
- Rhode Island +63%
- New Hampshire +62%
- Alaska +62%
- Nevada +61%
- Puerto Rico (smallest change) +12%
- West Virginia (smallest change) +26%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 125 mg / 31.25 mg clavulanate potassium | white powder | |
| 250 mg / 62.5 mg clavulanate potassium | white powder | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.